Endoscopic submucosal injection of adipose-derived mesenchymal stem cells ameliorates TNBS-induced colitis in rats and prevents stenosis
Authors:
- Eduardo Martín ArranzEAEduardo Martín Arranz
- María Dolores Martín ArranzMAMaría Dolores Martín Arranz
- Tomás RobredoTRTomás Robredo
- Pablo Mancheño-CorvoPMPablo Mancheño-Corvo
- Ramón MentaRMRamón Menta
- Francisco Javier AlvesFAFrancisco Javier Alves
- Jose Manuel Suárez de PargaJPJose Manuel Suárez de Parga
- Pedro Mora SanzPSPedro Mora Sanz
- Olga de la RosaOROlga de la Rosa
- Dirk BüscherDBDirk Büscher
- Eleuterio LombardoELEleuterio Lombardo
- Fernando de MiguelFMFernando de Miguel
Open Access
- 10 April 2018
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 9 (1) , 95
Abstract
Mesenchymal stem cells have potential applications in inflammatory bowel disease due to their immunomodulatory properties. Our aim was to evaluate the feasibility, safety and efficacy of endoscopic administration of adipose-derived mesenchymal stem cells (ASCs) in a colitis model in rats. Colitis was induced in rats by rectal trinitrobenzenesulfonic acid (TNBS). After 24 h ASCs (107 cells) or saline vehicle were endoscopically injected into the distal colon. Rats were followed for 11 days. Daily weight, endoscopic score at days 1 and 11, macroscopic appearance at necropsy, colon length and mRNA expression of Foxp3 and IL-10 in mesenteric lymph nodes (MLN) were analyzed. Endoscopic injection was successful in all the animals. No significant adverse events or mortality due to the procedure occurred. Weight evolution was significantly better in the ASC group, recovering initial weight by day 11 (− 0.8% ± 10.1%, mean ± SD), whereas the vehicle group remained in weight loss (− 6.7% ± 9.2%, p = 0.024). The endoscopic score improved in the ASC group by 47.1% ± 5.3% vs. 21.8% ± 6.6% in the vehicle group (p < 0.01). Stenosis was less frequent in the ASC group (4.8% vs. 41.2%, p < 0.01). Colon length significantly recovered in the ASC group versus the vehicle group (222.6 ± 17.3 mm vs. 193.6 ± 17.9 mm, p < 0.001). The endoscopic score significantly correlated with weight change, macroscopic necropsy score and colon length. Foxp3 and IL-10 mRNA levels in MLN recovered with ASC treatment. ASC submucosal endoscopic injection is feasible, safe and ameliorates TNBS-induced colitis in rats, especially stenosis.Keywords
Funding Information
- Instituto de Salud Carlos III (PI10/0317)
This publication has 70 references indexed in Scilit:
- Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell ApoptosisCell Stem Cell, 2012
- Intraperitoneal but Not Intravenous Cryopreserved Mesenchymal Stromal Cells Home to the Inflamed Colon and Ameliorate Experimental ColitisPLOS ONE, 2012
- Pretreatment with Interferon-γ Enhances the Therapeutic Activity of Mesenchymal Stromal Cells in Animal Models of ColitisStem Cells, 2011
- Bone Marrow Stromal Cell Transplants Prevent Experimental Enterocolitis and Require Host CD11b+ SplenocytesGastroenterology, 2011
- Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in ratsLife Sciences, 2008
- Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for HomingStem Cells, 2007
- Chemically induced mouse models of intestinal inflammationNature Protocols, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Cell Surface and Transcriptional Characterization of Human Adipose‐Derived Adherent Stromal (hADAS) CellsStem Cells, 2005
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987